{"id":356271,"date":"2025-08-29T06:14:07","date_gmt":"2025-08-29T06:14:07","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-genmab-as\/"},"modified":"2025-08-29T06:14:07","modified_gmt":"2025-08-29T06:14:07","slug":"how-to-buy-genmab-as","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/","title":{"rendered":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-356271","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131"},"description":"Genmab A\/S (GMAB) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizini, ad\u0131m ad\u0131m sat\u0131n alma s\u00fcrecini ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in uzman g\u00f6r\u00fc\u015flerini \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Genmab A\/S (GMAB) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizini, ad\u0131m ad\u0131m sat\u0131n alma s\u00fcrecini ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in uzman g\u00f6r\u00fc\u015flerini \u00f6\u011frenin."},"intro":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Genmab A\/S (GMAB), devrim niteli\u011findeki antikor terapileriyle kanser tedavisinin gelece\u011fini temsil ediyor. Bu Danimarkal\u0131 biyoteknoloji devi, bir ara\u015ft\u0131rma giri\u015fiminden ticari bir g\u00fc\u00e7 merkezine d\u00f6n\u00fc\u015ferek sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici bir f\u0131rsat sunuyor. GMAB'nin neden dikkatinizi hak etti\u011fini ve yenilik\u00e7i yolculuklar\u0131n\u0131n bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Genmab A\/S (GMAB), devrim niteli\u011findeki antikor terapileriyle kanser tedavisinin gelece\u011fini temsil ediyor. Bu Danimarkal\u0131 biyoteknoloji devi, bir ara\u015ft\u0131rma giri\u015fiminden ticari bir g\u00fc\u00e7 merkezine d\u00f6n\u00fc\u015ferek sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici bir f\u0131rsat sunuyor. GMAB'nin neden dikkatinizi hak etti\u011fini ve yenilik\u00e7i yolculuklar\u0131n\u0131n bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Genmab Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla, Genmab A\/S (GMAB) hisseleri NASDAQ borsas\u0131nda <strong>24,65 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, 2025 y\u0131l\u0131nda \u00f6nceki volatiliteden toparlanarak y\u0131lba\u015f\u0131ndan bu yana sa\u011flam bir performans sergiledi.<\/p> <p><strong>Takviminize not edin: 5 Kas\u0131m 2025<\/strong> kritik bir tarih. Genmab'\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine yol a\u00e7m\u0131\u015f ve bilgili yat\u0131r\u0131mc\u0131lar\u0131n bundan faydalanmas\u0131n\u0131 sa\u011flam\u0131\u015ft\u0131r.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 GMAB Hisselerini Nas\u0131l Etkiler?<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>22,10 $<\/td><td>%11,5 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>20,85 $<\/td><td>%6,0 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td><\/tr> <tr><td>6 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Rapor<\/td><td>19,40 $<\/td><td>%7,2 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>Pipeline G\u00fcncellemesi<\/td><td>18,25 $<\/td><td>%4,9 Art\u0131\u015f (pozitif veriler)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>17,80 $<\/td><td>%2,2 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>9 May 2024<\/td><td>Ortakl\u0131k Haberi<\/td><td>16,95 $<\/td><td>%5,0 Art\u0131\u015f (yeni i\u015f birli\u011fi)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle birka\u00e7 g\u00fcn i\u00e7inde %5-12 aras\u0131nda kazan\u00e7 sa\u011flar. Negatif sonu\u00e7lar ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur, ancak GMAB'nin g\u00fc\u00e7l\u00fc temelleri genellikle h\u0131zl\u0131 toparlanmay\u0131 destekler.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3> <p>Genmab hisseleri son alt\u0131 ayda <strong>etkileyici %27 getiri<\/strong> sa\u011flad\u0131:<\/p> <ul> <li><strong>Mart<\/strong>: 19,40 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li> <li><strong>Nisan<\/strong>: 21,80 $ (1. \u00e7eyrek kazan\u00e7 art\u0131\u015f\u0131)<\/li> <li><strong>May\u0131s<\/strong>: 23,10 $ (pipeline geli\u015fmeleri)<\/li> <li><strong>Haziran<\/strong>: 22,50 $ (piyasa d\u00fczeltmesi)<\/li> <li><strong>Temmuz<\/strong>: 24,20 $ (ilk yar\u0131 sonu\u00e7 beklentisi)<\/li> <li><strong>A\u011fustos<\/strong>: 24,65 $ (g\u00fc\u00e7l\u00fc kazan\u00e7lar teyit edildi)<\/li> <\/ul> <p>Bu y\u00fckseli\u015f e\u011filimi, yat\u0131r\u0131mc\u0131lar\u0131n Genmab'\u0131n i\u015f modeli ve pipeline potansiyeline olan g\u00fcveninin artt\u0131\u011f\u0131n\u0131 yans\u0131t\u0131yor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu<\/strong>: 32-38 $ (devam eden telif hakk\u0131 b\u00fcy\u00fcmesi ve pipeline kilometre ta\u015flar\u0131 ile) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p> <p><strong>2026 Projeksiyonu<\/strong>: 40-48 $ (yeni pazarlara geni\u015fleme ve ek ila\u00e7 onaylar\u0131)<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 55-65 $ (antikor terapilerinde hakimiyet ve k\u00fcresel pazar penetrasyonu)<\/p> <p><strong>2030 Vizyonu<\/strong>: 75-90 $ (sekt\u00f6r liderli\u011fi ve potansiyel \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler)<\/p> <p>11 analist aras\u0131nda ortak g\u00f6r\u00fc\u015f, mevcut seviyelerden %52 y\u00fckseli\u015f potansiyeli ile ortalama 37,60 $ fiyat hedefi ve <strong>\"Orta Derecede Al\"<\/strong> derecesidir.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: \u0130la\u00e7 onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez olabilir<\/li> <li><strong>Patent s\u00fcresi dolmalar\u0131<\/strong>: \u00d6nemli \u00fcr\u00fcnler sonunda jenerik rekabetle kar\u015f\u0131la\u015fabilir<\/li> <li><strong>D\u00f6viz riski<\/strong>: Gelirin %85'i Danimarka d\u0131\u015f\u0131ndan geliyor<\/li> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Pipeline adaylar\u0131 hedeflere ula\u015famayabilir<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>%19 gelir art\u0131\u015f\u0131<\/strong> 2025 ilk yar\u0131s\u0131nda (<a href=\"https:\/\/www.ainvest.com\/news\/genmab-reports-19-h1-2025-revenue-growth-completes-share-buyback-strategic-advancements-2508\/\">\u0130lk Yar\u0131 Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>30 milyar $ nakit pozisyonu<\/strong> stratejik yat\u0131r\u0131mlar i\u00e7in<\/li> <li><strong>EPCORE FL-1 \u00e7al\u0131\u015fmas\u0131 ba\u015far\u0131s\u0131<\/strong> \u00e7ift hedefe ula\u015farak<\/li> <li><strong>Biyoteknoloji sekt\u00f6r\u00fc r\u00fczgarlar\u0131<\/strong>: Yenilik\u00e7i kanser tedavilerine artan talep<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'ini ba\u015flang\u0131\u00e7ta GMAB'ye ay\u0131r\u0131n<\/li> <li><strong>Ortalama maliyet y\u00f6ntemi<\/strong> - T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - 5 Kas\u0131m kazan\u00e7 tarihi civar\u0131n\u0131 takip edin<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> - Biyoteknoloji yat\u0131r\u0131mlar\u0131 b\u00fcy\u00fck \u00f6d\u00fcller i\u00e7in sab\u0131r gerektirir<\/li> <\/ol> <p>Esprili bir bak\u0131\u015f: \"GMAB ticareti yapmak, bazen yan etkileri g\u00f6ze al\u0131p terap\u00f6tik faydalar\u0131 g\u00f6rmek i\u00e7in klinik deneme izlemek gibidir!\"<\/p> <h2>\u2705 Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeli hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>KYC gereksinimleri doland\u0131r\u0131c\u0131l\u0131\u011f\u0131 \u00f6nler<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"GMAB\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilitede fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>\u0130\u015flem \u00f6ncesi miktar ve fiyat\u0131 \u00e7ift kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonunuzu izleyin<\/td><td>Stop-loss ve kar hedefleri belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Neredeyse her b\u00fct\u00e7eyle ba\u015flayabilirsiniz<\/li> <li><strong>1 dakikal\u0131k do\u011frulama<\/strong> - Tek belge onay s\u00fcreci<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto, e-c\u00fczdanlar, banka transferleri mevcut<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> - GMAB gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 analizler<\/strong> - Karma\u015f\u0131kl\u0131k olmadan profesyonel ara\u00e7lar<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Genmab: Biyoteknoloji \u0130novasyon Lideri<\/h2> <p>Genmab A\/S, ara\u015ft\u0131rma odakl\u0131 bir giri\u015fimden <strong>ticari a\u015famada bir biyoteknoloji devi<\/strong> haline gelerek 14,95 milyar $ piyasa de\u011ferine ula\u015ft\u0131. \u015eirket, DuoBody\u00ae ve HexaBody\u00ae teknolojileri gibi \u00f6zel platformlar\u0131 kullanarak kanser tedavisi i\u00e7in devrim niteli\u011finde antikor terapileri geli\u015ftiriyor.<\/p> <p>Amiral gemisi \u00fcr\u00fcn\u00fc <strong>Darzalex<\/strong>, 2024 y\u0131l\u0131nda 7,98 milyar $ k\u00fcresel sat\u0131\u015f geliri elde ederek, devam eden ara\u015ft\u0131rma ve geli\u015ftirmeyi finanse eden istikrarl\u0131 telif geliri sa\u011flad\u0131. \u015eirket, piyasa zorluklar\u0131na ra\u011fmen 2025 ilk yar\u0131s\u0131nda <a href=\"https:\/\/www.ainvest.com\/news\/genmab-2025-earnings-surge-strategic-pipeline-momentum-position-high-growth-biotech-play-2508\/\">%19 gelir art\u0131\u015f\u0131<\/a> bildirdi ve g\u00fc\u00e7l\u00fc bir performans sergiledi.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Genmab'\u0131n bilim insanlar\u0131, kanser h\u00fccrelerini ayn\u0131 anda hedef al\u0131p ba\u011f\u0131\u015f\u0131kl\u0131k tepkilerini aktive eden antikorlar geli\u015ftirdi - sanki GPS kontroll\u00fc bir f\u00fcze yedek \u00e7a\u011f\u0131r\u0131yormu\u015f gibi! Bu \u00e7ift etkili teknoloji, hassas t\u0131bb\u0131n gelece\u011fini temsil ediyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Genmab Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla, Genmab A\/S (GMAB) hisseleri NASDAQ borsas\u0131nda <strong>24,65 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, 2025 y\u0131l\u0131nda \u00f6nceki volatiliteden toparlanarak y\u0131lba\u015f\u0131ndan bu yana sa\u011flam bir performans sergiledi.<\/p>\n<p><strong>Takviminize not edin: 5 Kas\u0131m 2025<\/strong> kritik bir tarih. Genmab&#8217;\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine yol a\u00e7m\u0131\u015f ve bilgili yat\u0131r\u0131mc\u0131lar\u0131n bundan faydalanmas\u0131n\u0131 sa\u011flam\u0131\u015ft\u0131r.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 GMAB Hisselerini Nas\u0131l Etkiler?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>22,10 $<\/td>\n<td>%11,5 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>20,85 $<\/td>\n<td>%6,0 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td>\n<\/tr>\n<tr>\n<td>6 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Rapor<\/td>\n<td>19,40 $<\/td>\n<td>%7,2 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>Pipeline G\u00fcncellemesi<\/td>\n<td>18,25 $<\/td>\n<td>%4,9 Art\u0131\u015f (pozitif veriler)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>17,80 $<\/td>\n<td>%2,2 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>16,95 $<\/td>\n<td>%5,0 Art\u0131\u015f (yeni i\u015f birli\u011fi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle birka\u00e7 g\u00fcn i\u00e7inde %5-12 aras\u0131nda kazan\u00e7 sa\u011flar. Negatif sonu\u00e7lar ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur, ancak GMAB&#8217;nin g\u00fc\u00e7l\u00fc temelleri genellikle h\u0131zl\u0131 toparlanmay\u0131 destekler.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3>\n<p>Genmab hisseleri son alt\u0131 ayda <strong>etkileyici %27 getiri<\/strong> sa\u011flad\u0131:<\/p>\n<ul>\n<li><strong>Mart<\/strong>: 19,40 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Nisan<\/strong>: 21,80 $ (1. \u00e7eyrek kazan\u00e7 art\u0131\u015f\u0131)<\/li>\n<li><strong>May\u0131s<\/strong>: 23,10 $ (pipeline geli\u015fmeleri)<\/li>\n<li><strong>Haziran<\/strong>: 22,50 $ (piyasa d\u00fczeltmesi)<\/li>\n<li><strong>Temmuz<\/strong>: 24,20 $ (ilk yar\u0131 sonu\u00e7 beklentisi)<\/li>\n<li><strong>A\u011fustos<\/strong>: 24,65 $ (g\u00fc\u00e7l\u00fc kazan\u00e7lar teyit edildi)<\/li>\n<\/ul>\n<p>Bu y\u00fckseli\u015f e\u011filimi, yat\u0131r\u0131mc\u0131lar\u0131n Genmab&#8217;\u0131n i\u015f modeli ve pipeline potansiyeline olan g\u00fcveninin artt\u0131\u011f\u0131n\u0131 yans\u0131t\u0131yor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 32-38 $ (devam eden telif hakk\u0131 b\u00fcy\u00fcmesi ve pipeline kilometre ta\u015flar\u0131 ile) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 40-48 $ (yeni pazarlara geni\u015fleme ve ek ila\u00e7 onaylar\u0131)<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 55-65 $ (antikor terapilerinde hakimiyet ve k\u00fcresel pazar penetrasyonu)<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 75-90 $ (sekt\u00f6r liderli\u011fi ve potansiyel \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler)<\/p>\n<p>11 analist aras\u0131nda ortak g\u00f6r\u00fc\u015f, mevcut seviyelerden %52 y\u00fckseli\u015f potansiyeli ile ortalama 37,60 $ fiyat hedefi ve <strong>&#8220;Orta Derecede Al&#8221;<\/strong> derecesidir.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: \u0130la\u00e7 onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez olabilir<\/li>\n<li><strong>Patent s\u00fcresi dolmalar\u0131<\/strong>: \u00d6nemli \u00fcr\u00fcnler sonunda jenerik rekabetle kar\u015f\u0131la\u015fabilir<\/li>\n<li><strong>D\u00f6viz riski<\/strong>: Gelirin %85&#8217;i Danimarka d\u0131\u015f\u0131ndan geliyor<\/li>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Pipeline adaylar\u0131 hedeflere ula\u015famayabilir<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>%19 gelir art\u0131\u015f\u0131<\/strong> 2025 ilk yar\u0131s\u0131nda (<a href=\"https:\/\/www.ainvest.com\/news\/genmab-reports-19-h1-2025-revenue-growth-completes-share-buyback-strategic-advancements-2508\/\">\u0130lk Yar\u0131 Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>30 milyar $ nakit pozisyonu<\/strong> stratejik yat\u0131r\u0131mlar i\u00e7in<\/li>\n<li><strong>EPCORE FL-1 \u00e7al\u0131\u015fmas\u0131 ba\u015far\u0131s\u0131<\/strong> \u00e7ift hedefe ula\u015farak<\/li>\n<li><strong>Biyoteknoloji sekt\u00f6r\u00fc r\u00fczgarlar\u0131<\/strong>: Yenilik\u00e7i kanser tedavilerine artan talep<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;ini ba\u015flang\u0131\u00e7ta GMAB&#8217;ye ay\u0131r\u0131n<\/li>\n<li><strong>Ortalama maliyet y\u00f6ntemi<\/strong> &#8211; T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; 5 Kas\u0131m kazan\u00e7 tarihi civar\u0131n\u0131 takip edin<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> &#8211; Biyoteknoloji yat\u0131r\u0131mlar\u0131 b\u00fcy\u00fck \u00f6d\u00fcller i\u00e7in sab\u0131r gerektirir<\/li>\n<\/ol>\n<p>Esprili bir bak\u0131\u015f: &#8220;GMAB ticareti yapmak, bazen yan etkileri g\u00f6ze al\u0131p terap\u00f6tik faydalar\u0131 g\u00f6rmek i\u00e7in klinik deneme izlemek gibidir!&#8221;<\/p>\n<h2>\u2705 Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>KYC gereksinimleri doland\u0131r\u0131c\u0131l\u0131\u011f\u0131 \u00f6nler<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;GMAB&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilitede fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flem \u00f6ncesi miktar ve fiyat\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu izleyin<\/td>\n<td>Stop-loss ve kar hedefleri belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Neredeyse her b\u00fct\u00e7eyle ba\u015flayabilirsiniz<\/li>\n<li><strong>1 dakikal\u0131k do\u011frulama<\/strong> &#8211; Tek belge onay s\u00fcreci<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto, e-c\u00fczdanlar, banka transferleri mevcut<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> &#8211; GMAB gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 analizler<\/strong> &#8211; Karma\u015f\u0131kl\u0131k olmadan profesyonel ara\u00e7lar<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Genmab: Biyoteknoloji \u0130novasyon Lideri<\/h2>\n<p>Genmab A\/S, ara\u015ft\u0131rma odakl\u0131 bir giri\u015fimden <strong>ticari a\u015famada bir biyoteknoloji devi<\/strong> haline gelerek 14,95 milyar $ piyasa de\u011ferine ula\u015ft\u0131. \u015eirket, DuoBody\u00ae ve HexaBody\u00ae teknolojileri gibi \u00f6zel platformlar\u0131 kullanarak kanser tedavisi i\u00e7in devrim niteli\u011finde antikor terapileri geli\u015ftiriyor.<\/p>\n<p>Amiral gemisi \u00fcr\u00fcn\u00fc <strong>Darzalex<\/strong>, 2024 y\u0131l\u0131nda 7,98 milyar $ k\u00fcresel sat\u0131\u015f geliri elde ederek, devam eden ara\u015ft\u0131rma ve geli\u015ftirmeyi finanse eden istikrarl\u0131 telif geliri sa\u011flad\u0131. \u015eirket, piyasa zorluklar\u0131na ra\u011fmen 2025 ilk yar\u0131s\u0131nda <a href=\"https:\/\/www.ainvest.com\/news\/genmab-2025-earnings-surge-strategic-pipeline-momentum-position-high-growth-biotech-play-2508\/\">%19 gelir art\u0131\u015f\u0131<\/a> bildirdi ve g\u00fc\u00e7l\u00fc bir performans sergiledi.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Genmab&#8217;\u0131n bilim insanlar\u0131, kanser h\u00fccrelerini ayn\u0131 anda hedef al\u0131p ba\u011f\u0131\u015f\u0131kl\u0131k tepkilerini aktive eden antikorlar geli\u015ftirdi &#8211; sanki GPS kontroll\u00fc bir f\u00fcze yedek \u00e7a\u011f\u0131r\u0131yormu\u015f gibi! Bu \u00e7ift etkili teknoloji, hassas t\u0131bb\u0131n gelece\u011fini temsil ediyor.<\/p>\n"},"faq":[{"question":"Genmab A\/S hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Genmab A\/S hisselerini sat\u0131n almak i\u00e7in NASDAQ listeli bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"GMAB\" sembol\u00fc ile arama yap\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in ve i\u015flemi onaylay\u0131n."},{"question":"Genmab hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in 32-38 $, 2026 i\u00e7in 40-48 $, 2028 i\u00e7in 55-65 $ ve 2030 i\u00e7in 75-90 $ aral\u0131\u011f\u0131nda fiyat tahminleri bulunmaktad\u0131r."},{"question":"Genmab'\u0131n en b\u00fcy\u00fck riski nedir?","answer":"Reg\u00fclasyon belirsizli\u011fi, patent s\u00fcresi dolmalar\u0131, d\u00f6viz riski ve klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 en \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar Genmab hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %3-5'i ile k\u00fc\u00e7\u00fck ba\u015flay\u0131p, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurup uzun vadeli d\u00fc\u015f\u00fcnmelidirler."},{"question":"Pocket Option Genmab hisseleri i\u00e7in neden uygundur?","answer":"Minimum 5 $ depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi, par\u00e7al\u0131 hisse al\u0131m\u0131 ve ger\u00e7ek zamanl\u0131 analiz ara\u00e7lar\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Genmab A\/S hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Genmab A\/S hisselerini sat\u0131n almak i\u00e7in NASDAQ listeli bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"GMAB\" sembol\u00fc ile arama yap\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in ve i\u015flemi onaylay\u0131n."},{"question":"Genmab hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in 32-38 $, 2026 i\u00e7in 40-48 $, 2028 i\u00e7in 55-65 $ ve 2030 i\u00e7in 75-90 $ aral\u0131\u011f\u0131nda fiyat tahminleri bulunmaktad\u0131r."},{"question":"Genmab'\u0131n en b\u00fcy\u00fck riski nedir?","answer":"Reg\u00fclasyon belirsizli\u011fi, patent s\u00fcresi dolmalar\u0131, d\u00f6viz riski ve klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 en \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar Genmab hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %3-5'i ile k\u00fc\u00e7\u00fck ba\u015flay\u0131p, dolar maliyeti ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurup uzun vadeli d\u00fc\u015f\u00fcnmelidirler."},{"question":"Pocket Option Genmab hisseleri i\u00e7in neden uygundur?","answer":"Minimum 5 $ depozito, h\u0131zl\u0131 do\u011frulama, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi, par\u00e7al\u0131 hisse al\u0131m\u0131 ve ger\u00e7ek zamanl\u0131 analiz ara\u00e7lar\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T06:14:07+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T06:14:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\",\"name\":\"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-29T06:14:07+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/","og_locale":"tr_TR","og_type":"article","og_title":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T06:14:07+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T06:14:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/","name":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-29T06:14:07+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":356272,"slug":"how-to-buy-genmab-as","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Genmab A\/S (GMAB) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-genmab-as\/"},"pt_AA":{"locale":"pt_AA","id":356267,"slug":"how-to-buy-genmab-as","post_title":"Como comprar a\u00e7\u00f5es da Genmab A\/S (GMAB) - Investimento em a\u00e7\u00f5es da Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-genmab-as\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/356271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=356271"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/356271\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=356271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=356271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=356271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}